Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05316181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)

Study acronym: KOV-HIPEC-02R
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 12, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2025 to Jun 30, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v6
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study sites: 1 to 3
    • Study description revised
    • Study title expanded, about 4 words
    v5
  3. 2 versions Re-verified since Apr 23, 2022, no change to tracked fieldsv3-v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2, 2022 to Apr 7, 2022
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Platinum-resistant recurrent epithelial ovarian cancer randomizing with or without cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC): KOV-02R, RECOVER
Trial Details
NCT Number NCT05316181
Lead Sponsor National Cancer Center, Korea
Conditions
(from sponsor)		 Epithelial Ovarian Cancer, Platinum Resistant, Recurrent Ovarian, HIPEC, Mitomycin, Cytoreductive Surgery
Related terms Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov